Ray Blanco’s FDA Profit Alert

Ray Blanco's FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

IMPORTANT: FDA Gives Approval to Durata Therapeutics for Its Incredible New Antibiotic

We've just received word that the Food and Drug Administration (FDA) has approved our PDUFA Booster Shot’s antibiotic drug for use in the United States. The stock is halted right now, meaning no one can buy or sell shares. Because of the Memorial Day holiday, the next chance to transact in Durata Therapeutics stock will be Tuesday, May 27. Paul is monitoring the situation and will send you an alert on what you should do with your Durata Therapeutics stock on Tuesday.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Ray Blanco’s FDA Profit Alert

The FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Josh Grasmick

Josh Grasmick is managing editor of Thechnology Profits Daily and associate editor of Technology Profits Confidential and Breakthrough Technology Alert. After graduating from Washington College with a degree in English, the self-described autodidact was interviewed by Time magazine for his novel entrepreneurship and worldwide eco-adventures. His experience with those in the fields of science,...

View More By Josh Grasmick